ACAD:NSD-ACADIA Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 43.63

Change

+0.76 (+1.77)%

Market Cap

USD 6.81B

Volume

2.16M

Average Target Price

USD 56.00 (+28.35%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-08-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+0.11 (+0.04%)

USD72.47B 34.39 28.70
REGN Regeneron Pharmaceuticals, Inc

-3.31 (-0.53%)

USD67.57B 31.73 22.00
SGEN Seattle Genetics, Inc

-0.79 (-0.49%)

USD29.26B N/A N/A
MRNA Moderna, Inc

-2.04 (-2.69%)

USD28.45B N/A N/A
RPRX Royalty Pharma plc

+1.97 (+4.70%)

USD26.58B 17.99 12.39
GMAB Genmab A/S

+0.17 (+0.47%)

USD23.47B 58.47 6.54
ALXN Alexion Pharmaceuticals, Inc

+1.15 (+1.12%)

USD22.77B 9.90 26.01
INCY Incyte Corporation

-0.37 (-0.38%)

USD22.13B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

-0.18 (-0.15%)

USD22.07B 190.17 114.09
BNTX BioNTech SE

-4.22 (-5.19%)

USD20.36B -99,999.99 N/A

ETFs Containing ACAD

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 2.36 % 0.79 %

-0.23 (-0.49%)

USD0.03B
BTEC Principal Healthcare Inno.. 1.82 % 0.42 %

-0.35 (-0.75%)

USD0.09B
DRDR:LSE iShares Healthcare Innova.. 1.45 % 0.40 %

-2.00 (-0.31%)

USD0.47B
HEAL:LSE iShares Healthcare Innova.. 1.45 % 0.40 %

-0.05 (-0.64%)

USD0.51B
AGED:LSE iShares Ageing Population.. 0.54 % 0.40 %

-0.01 (-0.17%)

USD0.28B
SIZ AGFiQ U.S. Market Neutral.. 0.37 % 2.82 %

N/A

USD0.88M
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.61 %

+0.02 (+0.12%)

USD0.73M
MOM AGFiQ U.S. Market Neutral.. 0.00 % 2.32 %

+0.01 (+0.03%)

USD5.81M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.99% 49% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.99% 49% F 59% F
Trailing 12 Months  
Capital Gain 50.40% 66% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.40% 66% D 81% B-
Trailing 5 Years  
Capital Gain 11.47% 70% C- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.47% 69% D+ 49% F
Average Annual (5 Year Horizon)  
Capital Gain 21.65% 63% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.65% 61% D- 52% F
Risk Return Profile  
Volatility (Standard Deviation) 60.10% 35% F 17% F
Risk Adjusted Return 36.02% 60% D- 39% F
Market Capitalization 6.81B 95% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.15 19% F 13% F
Price / Cash Flow Ratio -45.07 92% A- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -45.04% 72% C- 26% F
Return on Invested Capital -42.00% 71% C- 22% F
Return on Assets -24.87% 61% D- 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.15 43% F 32% F
Short Percent 10.78% 32% F 22% F
Beta 1.80 39% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.